Skip to main content

Table 1 hrHPV positivity (any and specific genotypes) for urine, vaginal and cervical samples

From: Urine collection in cervical cancer screening – analytical comparison of two HPV DNA assays

hrHPV result Assay
(total)
Urine positive
n, % (95%CI)
Vaginal positive
n, % (95%CI)
Cervical positive
n, % (95%CI)
McNemar test
Urine vs. vaginal
McNemar test
Urine vs. cervical
Any hrHPV (14 types)a Cobas
(n = 150)
27 18.0 (12.2–25.1) 44 29.3 (22.2–37.3) 36 24.0 (17.4–31.6) 0.01 0.05
Clart
(n = 150)
25 16.7 (11.1–23.6) 35 23.3 (16.8–30.9) 31 20.7 (14.5–28.0) 0.04 0.31
HPV16/18b,d Cobas
(n = 150)
6 4.0 (1.5–8.5) 17 11.3 (6.7–17.5) 15 10.0 (5.7–15.9) 0.01 0.02
Clart
(n = 150)
4 2.7 (0.7–6.7) 9 6.0 (2.8–11.1) 8 5.3 (2.3–10.2) 0.06 0.13
hrHPV other (12 types)c,d Cobas
(n = 150)
24 16.0 (10.5–22.9) 38 25.3 (18.6–33.1) 29 19.3 (13.3–26.6) 0.01 0.27
Clart
(n = 150)
21 14.0 (8.9–20.6) 31 20.7 (14.5–28.0) 29 19.3 (13.3–26.6) 0.04 0.17
  1. a Any hrHPV: HPV16 and/or HPV18 and/or HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68
  2. b HPV16/18: HPV16 and/or HPV18 including co-infections with hrHPV of other types
  3. c HrHPV other: HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 including co-infections with HPV16/18
  4. McNemars test comparing the hrHPV positivity proportions between sample types
  5. d Women with co-infections with HPV16/18 and hrHPV of other types appear in both sub-analyses
  6. % Row percentage